Biogen News

Repligen (RGEN) Down 10.9% Since Last Earnings Report: Can It Rebound?

Yahoo FinanceMay 31 23:31

Europe Approves Biogen's Tofersen For Adult Patients With Rare Type Of Neurodegenerative Disorder

On Thursday, the European Commission granted marketing authorization under exceptional circumstances and maintained orphan designation for Biogen Inc's (NASDAQ:BIIB) Qalsody (tofersen) for amyotrophic

BenzingaMay 31 22:25

Biogen (BIIB) Gets EU Approval for Rare Disease Drug Qalsody

Yahoo FinanceMay 31 22:17

European Commission Approves Biogen's QALSODY for ALS Treatment

Yahoo FinanceMay 31 16:25

Analysts' Opinions Are Mixed on These Healthcare Stocks: Gilead Sciences (GILD), Biogen (BIIB) and Argenx Se (ARGX)

TipRanksMay 31 11:00

Biogen Gets European Commission Approval for Qalsody

Biogen (BIIB) said late Thursday the European Commission granted marketing authorization for Qalsody, or tofersen, to treat adults with amyotrophic lateral sclerosis associated with a mutation in the

MT NewswiresMay 31 05:54

EU Approves Biogen Treatment for Genetic Form of ALS

Seeking AlphaMay 31 05:30

Biogen: SOD1-ALS Is Uniformly Fatal, Ultra-Rare Genetic Form of ALS Estimated to Affect Less Than 1,000 People in Europe >BIIB

Biogen: SOD1-ALS Is Uniformly Fatal, Ultra-Rare Genetic Form of ALS Estimated to Affect Less Than 1,000 People in Europe >BIIB

Dow JonesMay 31 05:00

Biogen Announces European Commission Grants Marketing Authorization For QALSODY To Treat SOD1-ALS In Adults; Maintains Orphan Designation

SOD1-ALS is a devastating, uniformly fatal, and ultra-rare genetic form of ALS estimated to affect less than 1,000 people in Europe1QALSODY is Biogen's third rare disease therapy to be approved in the

BenzingaMay 31 04:52

Express News | Biogen Receives European Commission Approval for Qalsody® (Tofersen), the First Therapy to Treat a Rare, Genetic Form of ALS

BreakingsMay 31 04:51

The Moderna Selloff Gains Steam. An Analyst Has a Few Theories Why. -- Barrons.com

By Josh Nathan-Kazis What began Tuesday as a puzzling dip in shares of the biotech Moderna accelerated into a larger selloff Wednesday. The stock was down 5.5% Wednesday morning, bringing the stocks

Barron'sMay 29 23:56

Qiagen (QGEN) Up 1.6% Since Last Earnings Report: Can It Continue?

Yahoo FinanceMay 29 23:30

Royal Bank of Canada: Biogen (BIIB.US) rating was reaffirmed and adjusted from superior to superior market rating, with a target price of $317.00.

Royal Bank of Canada: Biogen (BIIB.US) rating was reaffirmed and adjusted from superior to superior market rating, with a target price of $317.00.

Zhitong FinanceMay 29 22:02

RBC Capital Reiterates Outperform on Biogen, Maintains $317 Price Target

RBC Capital analyst Brian Abrahams reiterates Biogen (NASDAQ:BIIB) with a Outperform and maintains $317 price target.

BenzingaMay 29 21:59

Biogen Analyst Ratings

Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/29/2024 46.44% RBC Capital → $317 Reiterates Outperform → Outperform 05/23/2024 38.59% HC Wainwright &

BenzingaMay 29 21:58

Jeito Capital Announces the Acquisition by Merck & Co (NYSE: MRK) of Its Portfolio Company EyeBio for a Potential Value of $3 Billion

Jeito Capital announces the acquisition by Merck & Co (NYSE:MRK)of its portfolio company EyeBio for a potential value of $3 billion

GlobeNewswireMay 29 19:02

RBC Capital Sticks to Its Buy Rating for Biogen (BIIB)

TipRanksMay 29 18:46

Analysts Offer Insights on Healthcare Companies: Inari Medical (NARI), Biogen (BIIB) and SOPHiA GENETICS (SOPH)

TipRanksMay 28 18:50

Is Biogen Inc.'s (NASDAQ:BIIB) Recent Price Movement Underpinned By Its Weak Fundamentals?

Yahoo FinanceMay 28 18:30

Eisai (ESALY.US) /BIIB.US (BIIB.US) new Alzheimer's disease antibody drug approved for marketing in South Korea

Lecanemab can slow disease progression and reduce the rate of cognitive and functional decline.

Zhitong FinanceMay 28 15:52